... en anglais seulement...
Essential Medicines Biennial Report 20062007
the pharmaceutical scene in 20062007
Authors: Medicines Policy and Standards, Technical Cooperation for
Essential Drugs and Traditional Medicine
Editors: Finney, Elizabeth
Number of pages: 8
Publication date: 27/05/2008
Languages: English
WHO reference number: WHO/PSM/TCM/2008
http://www.who.int/medicines/areas/access/EssentialMedsBiennialReport06_07.p
df
Essential Medicines Biennial Report [pdf 2.25Mb]
International support for activities relating to essential medicines
continues to grow. Global funding mechanisms now include not only the Global
Fund to Fight AIDS, TB and Malaria and the Global Drug Facility, GAVI and
others, but also UNITAID. UNITAID was launched in 2006 following a decision
by France, Brazil, Chile, Norway and the United Kingdom to create an
international drug purchasing facility targeting treatment for high-burden
diseases...
\\\\\\\\\\\\\\\\\\\\\\
WHO Operational package for assessing, monitoring and evaluating country
pharmaceutical situations
Guide for coordinators and data collectors
Authors: TCM - Department of Technical Cooperation for Essential Drugs
Number of pages: 161
Publication date: December 2007
Languages: English
WHO reference number: WHO/TCM/2007.2
Full text... [pdf 1.24Mb]
http://www.who.int/medicines/publications/WHO_TCM_2007.2.pdf
The complexity of the pharmaceutical sector, with multiple and cross-cutting
factors that can influence access to and rational use of quality medicines,
makes it is extremely important to have a systematic method for assessing
the pharmaceutical situation at country, regional and global levels.
Pharmaceutical sector assessment, monitoring and evaluation aim to answer
the following vital questions: do people have access to essential medicines?
Are people getting medicines that are safe, effective and of good quality?
Are these medicines being used properly? Currently we have insufficient
information to answer such questions, but as part of its commitment to
assisting countries to improve access to and use of quality medicines, the
World Health Organization (WHO) has been developing tools to monitor and
evaluate pharmaceutical situations...
\\\\\\\\\\\\\\\\\\\\\
Measuring medicine prices, availability, affordability and price components
2ND EDITION
Authors: World Health Organization and Health Action International
Number of pages: 310
Publication date: 29/05/2008
Languages: English
WHO reference number: WHO/PSM/PAR/2008.3
http://www.who.int/medicines/areas/access/OMS_Medicine_prices.pdf
Full text [pdf 5.15Mb]
In 2003, the World Health Organization and Health Action International
published the first edition of Medicine prices a new approach to
measurement. The manual provided a draft methodology and tools for
conducting reliable medicine prices and availability surveys in a
standardized way, thereby facilitating national and international
comparisons. More than 50 surveys have now been conducted worldwide, and the
wealth of experience gained has led to a number of improvements in this
second edition of the manual. The survey methodology has been refined based
on the lessons learnt to date, and new methodologies and tools have been
developed in the areas of price component surveys and routine monitoring of
medicine prices and availability. As gathering evidence is only a first step
in improving access to affordable treatment, the new edition provides more
guidance on policy options and lines of action. Along with an updated
version of the automated data workbook, a CD-ROM of survey tools, resources
and background materials is included to ensure that the manual and
accompanying software are as user-friendly as possible.
\\\\\\\\\\\\\\\\\\\\\\\\\\\
WHO Pharmaceuticals Newsletter
(No. 2, 2008)
Authors: Quality assurance and Safety
Editors: Shanti Pal
Number of pages: 15
Publication date: 28 May 2008
Languages: English
http://www.who.int/medicines/publications/newsletter/PN2008_2.pdf
WHO Pharmaceuticals Newsletter - N° 2 2008 [pdf 245kb]
In this issue we bring you the recommendations from the fifth meeting of the
Advisory Committee on Safety of Medicinal Products (ACSoMP). Some of the
recommendations relate to ongoing projects, such as the patient safety pilot
project for expanding the scope of national pharmacovigilance centres;
others refer to new initiatives, such as developing indicators for measuring
pharmacovigilance capacity and the impact of interventions in countries.
Worldwide serious, acute allergic-type reactions have been reported in
patients who received contaminated heparin. We have included a brief summary
of regulatory actions that followed these events.
\\\\\\\\\\\\\\\\\\\\\\\\\\\
printable version
WHO Drug Information
Volume 22, Number 1, 2008
Authors: Quality Assurance and Safety of Medicines
Editors: Encrenaz, Christine
Number of pages: 40
Languages: English
Our first issue of WHO DRUG INFORMATION for 2008 opens with a feature
article on new regulatory systems being devised to address the growing
number of biosimilar products entering the market.
Pharmacovigilance Focus presents a report from the Annual Meeting of the WHO
Programme for International Drug Monitoring held in Buenos Aires, Argentina,
and proposes some interesting solutions for database reporting of adverse
drug reactions.
The Current Topics section provides information on new licensing mechanisms
for vaccines in the Americas, a report on counterfeit artesunate in
South-east Asia and the ort of a meeting on medicines pricing held with
Ministers from the Eastern Mediterranean countries.
The section on Safety and Efficacy gives the latest information on signals
and reports of adverse drug reactions, with other news from around the
world, including labeling changes. This is complemented by Regulatory Action
and News which provides the most recent developments from regulatory
authorities, and particularly those having an impact on decision-taking.
Several informational documents and events are reviewed and the journal
concludes with Recommended list number 59 of International Nonproprietary
Names (INN).
:: MAIN text [pdf 129kb]
http://www.who.int/medicines/publications/druginformation/issues/22_1_2008.p
df